HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Angeles Rovirosa Selected Research

Endometrial Neoplasms (Endometrial Cancer)

12/2023Are 7.5 Gy×2 fractions more efficient than 6 Gy×3 in exclusive postoperative endometrial cancer brachytherapy? A clinical and dosimetrical analysis.
6/2023Vaginal dilator use more than 9 months is a main prognostic factor for reducing G2‑late vaginal complications in 3D‑vaginal‑cuff brachytherapy (interventional radiotherapy)?
3/2022EROS 2.0 study: evaluation of two interventional radiotherapy (brachytherapy) schedules for endometrial cancer: a comparison of late vaginal toxicity rates.
2/2022Role of Brachytherapy in the Postoperative Management of Endometrial Cancer: Decision-Making Analysis among Experienced European Radiation Oncologists.
2/2022Exclusive 3D-brachytherapy as a good option for stage-I inoperable endometrial cancer: a retrospective analysis in the gynaecological cancer GEC-ESTRO Working Group.
1/2020Economic impact of decreasing the fraction number in vaginal cuff brachytherapy: A direct cost analysis.
1/2017Vaginal cuff brachytherapy in endometrial cancer - a technically easy treatment?
7/2015Can we shorten the overall treatment time in postoperative brachytherapy of endometrial carcinoma? Comparison of two brachytherapy schedules.
2/2013Daily schedule for high-dose-rate brachytherapy in postoperative treatment of endometrial carcinoma.
10/2011Three or four fractions of 4-5 Gy per week in postoperative high-dose-rate brachytherapy for endometrial carcinoma.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Angeles Rovirosa Research Topics

Disease

10Endometrial Neoplasms (Endometrial Cancer)
12/2023 - 10/2011
8Neoplasms (Cancer)
01/2024 - 04/2002
3Prostatic Neoplasms (Prostate Cancer)
02/2024 - 01/2016
3Uterine Cervical Neoplasms (Cancer of the Cervix)
09/2022 - 06/2017
2Carcinoma (Carcinomatosis)
01/2024 - 03/2008
1Hypogonadism (Hypergonadotropic Hypogonadism)
02/2024
1Vaginal Neoplasms (Cancer, Vaginal)
01/2024
1Pathologic Constriction (Stenosis)
01/2024
1Sarcoma (Soft Tissue Sarcoma)
01/2022
1Pelvic Neoplasms
01/2021
1Head and Neck Neoplasms (Head and Neck Cancer)
01/2017
1Squamous Cell Carcinoma (Epidermoid Carcinoma)
01/2017
1Carcinosarcoma
08/2014
1Neoplasm Metastasis (Metastasis)
10/2009
1Uterine Neoplasms (Uterine Cancer)
10/2009
1Breast Neoplasms (Breast Cancer)
11/2007
1Adenocarcinoma
08/2003
1Necrosis
04/2002

Drug/Important Bio-Agent (IBA)

1AndrogensIBA
02/2024
1Testosterone (Sustanon)FDA Link
02/2024
1PlatinumIBA
06/2022
1Carboplatin (JM8)FDA LinkGeneric
08/2003
1Paclitaxel (Taxol)FDA LinkGeneric
08/2003

Therapy/Procedure

19Brachytherapy
12/2023 - 11/2007
16Radiotherapy
02/2024 - 04/2002
4Drug Therapy (Chemotherapy)
01/2024 - 08/2003
3Therapeutics
02/2024 - 08/2003
1Lymph Node Excision (Lymph Node Dissection)
03/2022
1Enema (Enemas)
06/2017
1Psychotherapy Imagery (Guided Imagery)
11/2007